T he first essential discovery forming the basis for human gene therapy traces back >150 years to the experiments by Gregor Mendel who demonstrated that phenotypic traits are inherited by a defined pattern. 1, 2 It took almost another 8 decades until Avery, McLeod, and McCarty identified DNA as the carrier of genetic information 3 ( Figure 1 ). But it was really in the 1960s and 1970s, >10 years after the description of the double-helix, 4 when gene therapy became a reality. The deciphering of the genetic code, primarily by Nirenberg and Leder 5 and Morgan et al, 6 allowed the deduction of the protein sequence, including mutations, from a DNA sequence. This provided the theoretical framework for correcting mutations by introducing DNA that corrected missense or nonsense mutations in genes that rendered proteins either inactive or dominant negative, thus causing a particular genetic disorder. During the same period, Werner Arber, Daniel Nathans, and Hamilton O. Smith discovered restriction enzymes and how to use them as tools to manipulate precisely DNA. D98/AH-2 cells lack active HPRT (hypoxanthine guanine phosphoribosyl transferase) and are unable to grow in medium containing aminopterine, thymidine, and hypoxanthine as a sole purine source (hypoxanthine-aminopterin-thymidine medium). In 1962, Szybalska and Szybalski 7 demonstrated that introduction of DNA from D98S or D98/AG cells into D98/ AH−2 cells allowed the isolation of stable D98/AH-2 transformants that were able to grow in hypoxanthine-aminopterinthymidine medium, thus unambiguously demonstrating that the stable introduction of DNA into human cells can result in lasting phenotypic changes. 7, 8 The discovery that Lesch-Nyhan syndrome is caused by HPRT deficiency 9 immediately suggested that the efficient introduction of HPRT-encoding DNA into patients cells could ameliorate the symptoms of patients with LeschNyhan syndrome or could possibly even cure these patients. Unfortunately, the introduction of DNA, even with improved methods, such as DEAE (diethylaminoethyl) 10, 11 or calcium phosphate 12 transfection, remained for most cells inefficient. Viruses evolved over millions of years to introduce their viral genomes into host cells to hijack the cellular machinery for virus replication. That they might be useful to introduce stably a genetic material into the human host genome became evident when it was shown that SV40 13 and Rous sarcoma virus 14 can stably integrate their genome into mammalian cells and that certain proteins encoded by these integrated viral genome were actively expressed. 15 However, to be useful for gene therapy, the genome of viruses needed to be modified such that a potentially therapeutic protein was encoded within the viral genome. The first viruses that showed great promise for gene therapy were retroviruses. In the 1970s, 8 Temin 16, 17 reported that retroviruses convert their RNA genome into DNA, which is then stably integrated into the host genome, and Temin and Mizutani 18 and Baltimore 19 simultaneously described the existence of an RNA-dependent DNA polymerase in Rous sarcoma and Rauscher mouse leukemia virus, respectively. The discovery of these enzyme, which are now commonly known as reverse transcriptases, allowed the isolation of complementary DNAs that contained the contiguous coding sequence, from the start codon to the stop codon, of the therapeutic protein. This was, and is, essential for gene therapy because many genes are simply too big to be incorporated into viral vectors. For instance, the gene-encoding factor IX, deficiencies in which cause the bleeding disorder hemophilia B, is ≈33 kb long whereas the coding sequence, that is, the complementary DNA, is only 1386 bp in size.
The first foreign gene to be included into the genome of retroviruses was herpesvirus thymidine kinase. [20] [21] [22] But shortly thereafter, retroviral vectors encoding for HRPT were shown to be able to correct the phenotype of LeschNyhan cells. 23, 24 The first clinical trial to treat a genetically inherited disease with gene therapy was initiated in 1990 and aimed at treating adenosine deaminase deficiency, which causes a form of severe combined immunodeficiency. 25, 26 In the 2 patients who had been treated with retrovirally transduced autologous T-cells, significant improvements in both T-cell function as well as clinical improvements were observed. 27 Pioneering studies by Cavazzana-Calvo et al, 28 aimed at treating patients with X-linked severe combined immunodeficiency, demonstrated that patients with this disease could be cured by infusion of CD34 + cells that have been transduced with a recombinant Moloney retroviral vector encoding the γc-cytokine receptor. Unfortunately, several of the treated patients developed T-cell leukemias, and one patient died. 29 The
T-cell leukemias were caused by the integration of the retroviral genome near an oncogene, most prominently LMO2 29 demonstrating the risk of the use of retroviral gene transfer. Despite these setbacks, an improved protocol to treat adenosine deaminase severe combined immunodeficiency with a γ-retroviral vector encoding adenosine deaminase was highly successful 30, 31 and, in fact in 2016, the treatment of adenosine deaminase severe combined immunodeficiency was the first ex vivo gene therapy treatment approved for clinical use in Europe. 32 More recently, the treatment of children and young adults with relapsed/refractory acute lymphoblastic leukemia with T-cells that were genetically modified with a lentiviral vector to express a chimeric antigen receptor against the pan B-cell marker CD19 was approved by the Food and Drug Administration (FDA). 33 Whereas as numerous diseases, particularly of the hematopoietic system, lend themselves to ex vivo gene therapy, other disorders, for instance muscular dystrophies, Parkinson disease, Alzheimer disease, and heart failure, to name a few, require in vivo gene therapy. From a safety point of view, treatment with nonviral approaches is the most attractive. This is likely the main reason why of the >2400 gene therapy clinical trials >20% used so-called naked DNA or DNA complexes with cationic lipids. Unfortunately, similarly to in vitro transfection of cells, in vivo transfection efficiencies of target cells are low. Clearly, much work needs to be done before this attractive gene delivery modality can be used widely to deliver therapeutic genes. Adenoviral vectors are able to transduce efficiently most cell types, at least ex vivo. It is not surprising then that adenoviral vectors were also tested as therapeutic gene delivery vehicles in vivo. Especially in the second half of the 1990s, 34 adenoviral vectors were used extensively in clinical trials. Unfortunately, adenoviral vectors trigger a strong immune response. 34 Tragically, in 1999, Jesse Gelsinger, an 18-year-old patient who was part of a clinical trial to treat ornithine transcarbamylase deficiency by injection of an adenoviral vector encoding ornithine transcarbamylase, developed a fulminant immune response against the adenoviral vector, which resulted in multiorgan failure and ultimately the patient's death. This tragedy was a dramatic setback for the entire field of gene therapy, and it is likely the main reason that the use of adenoviral vectors is now mostly restricted to cancer therapy and vaccinations, where an immune response can be beneficial.
Adeno-associated virus (AAV) was originally identified as a contamination in an adenoviral culture. 35 AAVs are nonenveloped, single-stranded DNA viruses that are members of the parvoviridae family and the genus dependovirus. AAVs are defective viruses that can only replicate in the presence of a helpervirus, in particular adenovirus and herpesvirus. 36 Recombinant AAV vectors (rAAVs), first described in 1994 by Hermonat et al, 37 are especially attractive for gene therapy for several reasons, among them:
1. rAAVs are able to infect both dividing and nondividing cells. 36 At least in postmitotic cells, rAAVs lead to long-term transgene expression, even in the absence of genome integration because rAAV DNA largely persists as episomes. 36 2. The only cis-elements required for rAAV vectors are the inverted terminal repeats that flank the therapeutic expression cassette and, consequently, rAAVs don't express any viral protein. This is likely a key reason for the low immunogenicity of AAV vectors. 36 3. Together the natural AAV serotypes, and the large number of AAV variants isolated by various approaches, 38 display broad but distinct tissue tropism. As a result of these favorable properties, to date, rAAVs are arguably the most promising gene delivery vehicles for in vivo gene therapy.
rAAVs are studied as gene delivery vehicles for both the treatment of inherited disorders, as well as acquired diseases. Among the treatments of monogeneic inherited diseases with rAAV, the treatment of lipoprotein lipase deficiency with an AAV1 vector expressing the defective protein (Glybera) is particular notable because it was the first AAV gene therapy approved for clinical use in Europe and, in fact, the entire Western World. 39 Strikingly, however, UniQure did not apply for a license renewal for the continued clinical use of Glybera because of a lack of demand. 33 The experience with Glybera serves as a cautionary tale for the use of rAAVs to treat ultrarare diseases because it demonstrates that, even if clinically effective, gene therapy of such disorders might not be economically viable. Going forward, establishing appropriate pricing and reimbursement approaches will become increasingly important as gene therapy will mature into a broadly used treatment modality.
Currently, the most promising areas for the successful and economically viable use for AAV gene therapy are in the treatment of inherited retinal disorders, especially Leber congenital amaurosis (LCA), 40 and hemophilias, 41 particularly hemophilia B. The treatment of inherited retinal disorders is especially attractive because subretinal delivery of the AAV vector results in high local vector concentrations, which allows the efficient transduction of the target cells. Moreover, the eye is immune privileged, and the ocular-blood barrier reduces off-target transduction. 40 LCA type 2 is characterized by progressive vision loss, starting in infancy, and complete blindness in early adulthood. LCA type 2 is an autosomal recessive disorder that is caused by mutations in the RPE65 gene. After a large number of preclinical studies, including studies in a naturally occurring dog model, several clinical trials have shown great promise in treating this disease with AAV vectors encoding wild-type RPE65 (for an excellent review of gene therapy for inherited retinal disorders, see 40 ). In a seminal phase 3 clinical trial to treat LCA type 2 with an AAV2 vector encoding RPE65, 65% of patients treated, but none of the control patients met the primary end point (an improvement in a standardized multiluminance mobility test 1 year after treatment) and several secondary end points. 42 Based on these results, the US FDA recently approved the use of AAV2.RPE65 (brand name Luxturna; Sparks Therapeutics) for the treatment of LCA type 2, 43 making Luxturna the first AAV gene therapy to receive regulatory approval in the United States.
Factor IX deficiency is the underlying cause of hemophilia B. During the past years, intense research efforts have been devoted to develop AAV gene therapy to treat or cure this disease. Because the liver is the natural organ of factor IX production and hepatocytes are largely nondividing, much of the effort has concentrated on delivering an AAV vector encoding factor IX to the liver. A 2011 breakthrough study by Nathwani et al 44 demonstrated that delivery of wild-type factor IX with an AAV8 vector can result in clinically significant factor IX levels. Moreover, clinically significant factor IX levels were sustained for at least 3 years. 45 Since then, a plethora of clinical trials for hemophilia A and B have been initiated, and in at least 2 trials using a gain-of-function mutant, factor IX-R338L Padua, factor IX activity levels of 18% to 50% have been achieved (reviewed in 41 , see also 46 ). These promising results suggest that gene therapy to treat hemophilia B with systemically delivered rAAVs will most likely be used in the clinic in the not too distant future.
Cardiomyocytes, similarly to hepatocytes, are largely nondividing cells and are therefore promising target cells for AAV vectors. Given the enormous clinical need for the development of improved treatment options of both inherited and acquired cardiovascular diseases, it is not surprising that extensive preclinical research has been performed to test AAV vectors to treat cardiovascular diseases, most prominently heart failure. These intense efforts resulted in a plethora of successful studies, especially in rodents [47] [48] [49] [50] but also in preclinically relevant large animal models. [51] [52] [53] [54] [55] Based on extensive preclinical studies focused on delivering the cardiac isoform of the sarcoplasmic reticulum calcium ATPase pump, a doseescalating First in Man clinical study was initiated in patients with severe heart failure. 56 Phase 1 of the CUPID (calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease) trial demonstrated the safety of delivering an AAV1 vector encoding SERCA2a (sarcoplasmic/endoplasmic reticulum Ca 2+ ATPase 2a) via antegrade intracoronary infusion and indicated potential clinical benefit at a dose of 10 13 vg. 57, 58 Based on these encouraging results, an international, randomized, double-blind, placebo-controlled, phase 2b trial was initiated. 59 Unfortunately, the CUPID2b trial failed to meet both its primary (time to recurrent events, defined as hospital admission because of heart failure or ambulatory treatment for worsening heart failure) and secondary end points. 60, 61 These disappointing results raise, of course, the question why the CUPID2b trial did not meet its end points. By far, the most likely cause is a failure of delivering sufficient amounts of the vector genome to cardiomyocytes. In fact, despite the fact that the patients enrolled did not harbor any detectable neutralizing antibodies against AAV1, the reported results indicate that even in the sample with the highest AAV genome copy number (anterior septum of a patient in the high-dose group, 1e13 AAV1.SERCA2a vector genomes), <2% of all cardiomyocytes contained an vector genome and thus would have been able to express vector-derived SERCA2a. 61 The delivery method used for intracoronary infusion may have been inefficient. In fact in preclinical studies using a sheep model of heart failure, a recirculating method of delivering AAV1.SERCA2a was vastly superior to antegrade injections in terms of vector uptake to the myocardium. 62 Clearly, the efficiency of the delivery of the therapeutic genome to cardiomyocytes needs to be improved. Potential, mutual nonexclusive, approaches to achieve this include an increase in vector dose, methods to efficiently and safely deliver genes in vivo, improvements in the design of the vector application, and the development of AAV variants with enhanced tropism for human cardiomyocytes. We will discuss ongoing efforts to address these approaches in detail below.
Large Animal Gene Therapy Studies
In vitro and rodent studies allow the identification of promising gene therapy approaches. Although rodent studies offer cost-effective and time-efficient evaluation of promising approaches in vivo, large differences in physiology and size of the body (and the heart) compared to humans offer no guarantee in achieving the same positive effects in patients. Validation of therapeutic efficacy and confirmation of safety in more clinically relevant species are essential for successfully translating new therapies into early phase clinical trials. Importantly, this is also the key step for determining appropriate dose and modes of delivery for future human application. In this section, we will provide an overview of large animal gene therapy studies for building a bridge from bench to early phase clinical trials.
Disease Phenotype
The efficacy of gene therapy needs to be examined in diseased models to evaluate its functional effects. Careful consideration is necessary for choosing the right animal model based on the expected gene therapy effects and target patient population. For example, biological pacemaker gene therapies 63 should use animal models of sick sinus syndrome or atrioventricular block, whereas regenerative therapies 64 should use models with significant myocardial scar/fibrosis. If the therapy is going to be applied to the general heart failure population, therapeutic efficacy should be tested in both ischemic and nonischemic heart failure models because they exhibit large phenotypic differences. The following section provides a brief overview of large animal models that have been used in previous gene therapy studies and those of potential interests for future studies.
Ischemic Models
Percutaneous or surgical induction of myocardial infarction is the most widely used large animal models of acute [64] [65] [66] and chronic heart failures. 53, [67] [68] [69] However, location of coronary artery occlusion, duration of ischemia to reperfusion (ranging from <1 hour to permanent), and timing of therapeutic application significantly influence disease phenotype and can result in large differences in the study outcome. Gene therapy in acute or subacute myocardial infarction may be subject to strong inflammatory responses, and there are chances of gene transduction in nontarget cells, such as immune cells. In addition, there are chances of losing cells after successful gene transduction because of ongoing ischemia and inflammation. Genes that support myocyte survival, reduce inflammatory response, prevent arrhythmia, or improve ischemia may be good candidates to be examined using these models. In contrast, chronic heart failure models, usually after >1 month post-myocardial infarction, are characterized by established scar and remodeling in the noninfarcted myocardium, including hypertrophy, dysfunction, fibrosis, slightly but significantly increased cell death, and calcium dysregulation. Genes aiming at correcting the abnormalities in remodeled myocardium may be examined in this model. Another commonly found chronic ischemic heart condition is a hibernating myocardium. Slowly progressing coronary stenosis induces viable but dysfunctional myocardium, which causes angina symptoms and predisposes patients to sudden arrhythmic deaths. Animal models of hibernating myocardium 70, 71 can be used to examine genes with angiogenic properties to relieve ischemia and revitalize hibernating myocardium. 71, 72 It is important to note that long-term transgene expression is likely required for targeting chronic heart failure.
Nonischemic Models
A large variety of nonischemic heart failure models have been described. These include heart failure models induced by tachy-pacing, 73 mitral regurgitation, 55 aortic banding/stenosis, 74 renal wrapping, 75 and drug toxicity, to name a few. Gene therapy is usually tested in chronic stages of these models both to evaluate effects on prevention of disease progression and on reversal of the disease. In contrast to the ischemic models that have a heterogenous cardiac composition of scar and myocardium, these models have global abnormalities in the myocardium. Because there are likely more remaining cardiomyocytes in nonischemic heart failure, the efficacy of gene therapy targeting cardiomyocytes may yield better efficacy compared with the ischemic models, in which large areas of myocytes are replaced by scar tissue. Aortic banding and renal wrapping models present abnormality in diastolic function and may attract more interest in future preclinical testing because the high prevalence and lack of effective therapies targeting clinical heart failure with preserved ejection fraction remain a challenge in clinical heart failure management.
Arrhythmia Models
Inducing biological pacemaker cells by gene transfer is an attractive approach that can potentially replace surgical pacemaker implantations in patients with sick sinus syndrome and atrioventricular conduction abnormalities. Cardiac ablation techniques have been applied to induce large animal models of conduction abnormalities. 76 For studying gene therapy targeting atrial tachycardias, tachy-pacing-induced models have been used. 77 Meanwhile, reproducible induction of ventricular tachycardia in animal models remains challenging 78 and relies on ischemia models, which may have large variability in induction rate depending on the size, transmurality, and the location of the infarct. Chronic ischemic models with hibernating myocardium are highly susceptible to arrhythmic death 70 ; however, antiarrhythmic gene therapy using this model has not been examined yet.
Pulmonary Hypertension (PH) and Right Ventricular
Failure Models PH and associated right ventricular failure is another clinically important problem with limited therapies. 79 Pulmonary vascular remodeling is the central pathophysiology in disease progression in different classes of PH; however, clinically established treatments mainly exert their effects through vasodilatory mechanisms. Modifications of genes in the vascular cells may be able to tackle more fundamental part of the disease. Models of PH in large animals include those subsequent to left ventricular (LV) failure, hypoxia induced, pulmonary vein banding, and pulmonary artery embolization. Using the pulmonary vein banding-induced PH model, our group recently showed that inhalational AAV1.SERCA2a gene therapy prevents progressive pulmonary vascular remodeling and right ventricular failure.
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Transgenic Animal Models Some of the failures in previous clinical gene therapy studies, despite clear efficacy in preclinical studies, are considered at least partly because of the presence of comorbidities in clinical heart failure, such as diabetes mellitus. Recent advances in transgenic large animal models offer replication of these diseases in large animals by genetic modification. Hinkel et al 72 used transgenic diabetic animals with chronic ischemia model to examine the effect of vascular endothelial growth factor-A and thymosin β 4 gene therapy and demonstrated that animals with diabetes mellitus have lower efficacy of gene therapy compared with the animals without diabetes mellitus. This study supports the contributions of comorbidities on attenuating therapeutic efficacy in clinical patients, which is not only the case for gene therapy but also for any therapeutics in general. Other genemodified pig modes are being created, 81 and the repertories are increasing at a rapid pace. Thus, transgenic large animal models are an emerging research tool that can improve our prediction of clinical trial outcomes. In addition, transgenic large animals with specific gene mutations will be an excellent preclinical testing tool for genome editing approaches.
Approach to Increase the Transduction Efficiencies of Cardiomyocytes
As mentioned above and described in detail below, phase 2b of the CUPID trial failed to meet its primary and secondary end points, 60 the most likely reason being the inefficient delivery of the therapeutic transgene, SERCA2a. 60 In addition to increasing the dose of rAAV encoding the transgene, there are 2 principal approaches: (1) optimize the delivery method approach of the AAV vector, or (2) isolating AAV variants with increased tropism for cardiomyocytes. We will discuss both of these areas of research below.
Modes of Cardiac Gene Delivery
Mode of delivery is an important yet sometimes overlooked subject in translating new therapeutic approaches toward the clinic. For gene therapy, although intravenous injection of AAV9 is capable of cardiac-specific targeting in rodents, to date no vectors have successfully shown robust transgene expression with simple intravenous injection in advanced mammals. Several cardiac-targeted delivery approaches were proposed and examined in large animal models to improve cardiac vector uptake and distribution (Figure 2 ). Both surgical and percutaneous approaches are available, and we will briefly discuss features of these approaches in this section.
Surgical Approaches
Although being more invasive than percutaneous approaches, surgical approaches have advantages in direct visualization and firm-flexible manipulation. Intramyocardial injection of vectors using thin needles have been examined in previous angiogenic gene therapy studies 82 and is a reliable method when the patients have planned open-chest surgery. However, unlike in rodents, the areas that can be covered by small amount of vector injection are usually limited, and epicardial vasculatures further limit coverage. Gene painting is a unique method for targeting atria, which are difficult to target with other delivery methods. 83 Addition of elastase on adenoviral gene therapy using this method transduced the atrial cells to 100% in a pig model.
Percutaneous Approaches
Taking advantage of advances in catheter-based coronary interventions and cardiac ablations, percutaneous cardiac delivery is also available for cardiac gene therapy. Antegrade intracoronary artery delivery being the most simple method, many modifications on vascular delivery have been examined in large animal models, including stop-flow delivery with coronary artery/venous occlusion, 84 retrograde infusion, 85 and vector recirculation. 62, 86 To date, antegrade delivery has been the most popular in targeting heart failure patients with gene therapy, but one trial used retrograde infusion (RETRO-HF [Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Retrograde Delivery to Cohorts of Adults With Ischemic Heart Failure]). Results of this approach have not been released and safety/efficacy of other approaches in human remain unknown. Endocardial injection catheters have also been developed for this purpose, and one clinical trial delivered plasmid DNA using this approach. 87 Unfortunately, we currently do not have strong evidence that these approach can result in robust gene expression in human heart, partly owing to difficulty in obtaining cardiac tissue samples from patients. Generally, delivery approaches with higher transgene efficiency in large animals is associated with higher invasiveness. Therefore, balance between the efficacy and safety needs to be considered depending on gene of the interest, patient population, and desired transgene distribution. We have provided advantages and limitations of gene delivery methods that have been tested in clinically relevant animals in Table 1 .
Validating Efficacy Before Human Testing
Using clinically relevant animal models and delivery methods, appropriate study design for evaluating the efficacy of gene therapy is essential for clinical translation. The goals of large animal experiments are not only to reproduce previous efficacy results in bench studies but also to determine optimal delivery route, vector dose, safety, and optimal end points for future studies. Taking advantage of physiological and anatomic relevance to humans, large animal study is capable of evaluating physiological, structural, neurohormonal, and molecular changes associated with gene therapy. It is important that not only one of these parameters (usually the primary end point) show positive result but also all the evaluated secondary end points have trends toward improvement. Discrepancy in large animal studies and rodent studies should be examined thoroughly, and modifications should be done at this stage before getting into the clinical trials.
Evaluating Safety
Large animal study is also the key step for evaluating safety before clinical examination of new therapeutics. As we have little knowledge in how vectors and genes behave in vivo after cardiac gene delivery, potential adverse side effects need to be thoroughly excluded. These include, but are not limited to, vector/vehicle immune response, deleterious effects as a result of off-target expression, and potential negative effects on cardiac contractility, remodeling, and arrhythmias. Here, we briefly describe comprehensive toxicology and safety evaluations that we conducted for our previous gene therapy studies 51, 55 to obtain FDA approval and assure safety for human testing. First, because the gene delivery and the expressed proteins can all cause immune responses and inflammation, we evaluated both acute and chronic immune responses. Cardiac tissues were histologically examined for presence of T-cells, and we found no evidence of T-cell recruitment with gene therapy at early (5 day), mid (30 day), and chronic (90 day) time points after vector delivery. 88 In contrast, we found increased humoral immune response after AAV delivery; however, no detrimental effects were detected with increased antibodies against the vector. Second, to thoroughly exclude harmful off-target effects, animal growth, blood chemistry, and examination of >50 tissues were performed with histological evaluations on tissues from all major organs. Finally, to ascertain the lack of potential negative effects on the heart, we conducted multiple echocardiographic studies, ECG studies, continuous arrhythmia monitoring with loop recorder, dobutamine stress test, ex vivo electrophysiology studies using myocardial tissues, and detailed cardiac histological evaluations. Although these are time-consuming and labor-intensive works, we think this step is essential for clinical translation of cardiac gene therapy because establishing the safety is equally important to showing the efficacy before human testing.
Previous Clinical Trials of Cardiac Gene Therapy
Gene therapy was initially used to promote angiogenesis by overexpressing angiogenic factors. The majority of these trials used plasmid DNA or adenoviral vectors, and although some of the trials proceeded to phase 3, none of them successfully translated into clinical practice. The results of these trials are reviewed elsewhere. 89, 90 Here, we review more recent clinical trials that targeted patients with heart failure.
CUPID Trails
CUPID trials are part of an AAV1.SERCA2a gene therapy program that was initiated in May 2007. During the past decade, the program has progressed to phase 2b but failed to demonstrate significant therapeutic efficacy in the most recent phase 2b trial. Briefly, the first part of the trial (phase 1b) was a dose-escalation open-label study that eventually included 12 patients with different doses of AAV1.SERCA2a delivered through the intracoronary route. Safety of the vector using1.0×10 13 DNase resistant particles (DRP) was demonstrated. 57 Subsequently, a total of 39 patients were recruited and randomly assigned to low-dose (6×10 11 DRP), mid-dose (3×10 12 DRP), high-dose (1×10 13 DRP) of AAV1.SERCA2a or placebo with a ratio of 8:8:9:14. After 12 months of followup, high-dose group exhibited significantly better outcome in prespecified composite end point, which included 6 different variables (New York Heart Association class, Minnesota Living With Heart Failure Questionnaire, 6-minute walk test, peak maximum oxygen consumption, N-terminal prohormone brain natriuretic peptide levels, and LV end-systolic volume). 58 Furthermore, number of cardiovascular events was reduced and time to these events was prolonged in high-dose group compared with the placebo group. These positive effects sustained for long term, and a 3-year follow-up of these patients exhibited a dramatic 82% decrease in recurrent clinical events after 1×10 13 DRP AAV1.SERCA2a treatment. 61 The phase 2b, multicenter, international, double-blind, placebocontrolled trial followed these trials and enrolled 250 patients with chronic systolic heart failure with a 1:1 ratio assignment to the placebo or 1×10
13 DRP of AAV1.SERCA2a treatment. In contrast to phase1b/2a trial, New York Heart Association class II patients were also included and comprised 18% of the trial population. In this larger trial, time to recurrent clinical events was not different between the groups after a mean follow-up of 17.5 months, thus the primary end point was not met. 60 Similarly, secondary end point (time to first terminal event) also failed to achieve difference between the groups. No signs of adverse side effects attributed to the gene therapy were noted.
AGENT-HF
The AGENT-HF (NCT01966887) trial was a single center, randomized, double-blind, placebo-controlled trial in adult patients with New York Heart Association class III and IV ischemic or nonischemic HF and LV ejection fraction ≤35%.
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Eligible patients were randomized to receive a single intracoronary infusion of either 1×10 13 vg of AAV1.SERCA2a or placebo. 91 The primary end point was change in LV end-systolic volume, measured by cardiac computed tomography at 6-month follow-up. The trial was planned for 40 patients, but the trial was terminated prematurely after the neutral results of the CUPID-2b trial. At the time of termination, 9 patients had been randomized, and 5 patients had been infused with AAV1. SERCA2a and 4 with placebo, respectively. At 6 months, LV end-systolic volume was increased in both groups: median (interquartile range) in AAV1.SERCA2a versus placebo: 13 mL (13, 14 mL) versus 3.5 mL (−36, 36.5 mL), P=0.74. The mean difference between groups was 11.4 mL in favor of placebo. No safety issues were noted. Similarly, pooled estimates on 32 subjects from CUPID-1 and AGENT-HF studies (AAV1-CMV-Serca2a Gene Therapy Trial in Heart Failure) did not show any differences in 6-month changes in LV endsystolic volume, LV ejection fraction, N-terminal pro-B-type natriuretic peptide between AAV1.SERCA2a versus placebo. AGENT-HF failed to demonstrate any improvement in ventricular remodeling in response to AAV1.SERCA2a. In the one patient who was transplanted and myocardial tissue was available, there was no detectable transgene DNA.

SERCA-LVAD
The SERCA-LVAD trial (Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device) was a UK-based trial assessing the safety and feasibility of delivering AAV1.SERCA2a to adult patients with an LV assist device inserted for chronic heart failure. Enrolled subjects were randomized to receive a single intracoronary infusion of AAV1.SERCA2a or placebo control in a double-blinded design, stratified by presence of neutralizing antibodies to AAV. Elective endomyocardial biopsy was performed at 6 months unless the subject had received cardiac transplantation, with myocardial samples assessed for the presence of exogenous viral DNA from the treatment vector. Safety assessments, including ELISPOT (Enzyme-Linked ImmunoSpot), were serially performed. Although designed as a 24 subject trial, recruitment was stopped after 5 subjects had been randomized and received infusion because of the neutral results from the CUPID-2b trial. Overall, 5 patients were enrolled in the study. Once again, levels of detectable transgene DNA were low, and no functional benefit was observed. There were no safety concerns in this small cohort of patients.
STOP-HF
STOP-HF (Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients with Heart Failure) was a phase 2, double-blind, randomized, placebo-controlled trial that tested the efficacy and safety of catheter-based endomyocardial delivery of plasmid stromal cell-derived factor-1. A total of 93 patients were enrolled and assigned to placebo, 15 mg or 30 mg dose of plasmid stromal cell-derived factor-1 with a 1:1:1 ratio. The primary end point was a composite of change in 6 MWD (SixMinute Walk Distance) and MLWHFQ (Minnesota Living With Heart Failure Questionnaire) from before to 4 months after gene therapy. Although this primary end point was not met, the authors found signs of improvement in high-dose treated patients in other parameters, such as LV remodeling and N-terminal pro-B-type natriuretic peptide. 87 Long-term followup data of these patients have not been announced. Retrograde infusion of plasmid stromal cell-derived factor-1 was also examined in parallel, but this result is also not available.
AC6 Gene Transfer for Congestive Heart Failure
Adenylyl cyclase 6 (AC6) gene transfer trial used adenovirus-5 to deliver AC6 to increase cardiac cAMP in patients with chronic heart failure. This was a randomized, doubleblind, placebo-controlled, phase 2 trial enrolling 56 patients. They were randomized to receive placebo or 1 of 5 different doses of Ad5.AC6 (3.2 × 10 9 to 10 12 virus particles) through the intracoronary route. Primary end points included changes in exercise duration, LV ejection fraction, and peak rates of +dP/dt and −dP/dt. Although LV ejection fraction improved significantly after the gene therapy, there was also a large improvement in the placebo-treated control group which resulted in nonsignificance in the intergroup comparison. 92 Changes in other variables did not show significant improvements. Despite the concerns on strong immune response to adenoviral vector that was observed previously, this study did not report any evidence of strong immune response against the vector.
Potential Reasons for Neutral Results
Although STOP-HF and AC6 gene transfer trials reported possible beneficial effects in secondary analysis, none of above described trials were able to meet the primary efficacy end points. This fact can be attributed to various reasons, including those related to vectors, genes, delivery methods, patient population, and study end points (Table 2 ). It is likely that multiple factors contributed, and identification of the source of trial failure remains challenging. Nevertheless, contemplation on available data suggests that robust long-term expression of transgenes were not achieved to sufficiently alter patients' outcomes. In the CUPID-2b trial, analysis of available cardiac tissues from patients who underwent transplantation revealed minimal cardiac uptake of viral vectors which was substantially lower compared with preclinical trials. It is unlikely that meaningful transgene expression was achieved with this amount of viral uptake. Both STOP-HF and AC6 trials used vectors that allow short-term expression, and indeed AC6 gene transfer showed only transient improvement in LV ejection fraction. Because chronic heart failure is a sustained and often progressive condition, temporal overexpression of genes may not be sufficient to change the overall course. Strategies to achieve efficient long-term gene expression in humans are sought to change the paradigm. In addition, although STOP-HF and AC6 trials reported potential benefit of these therapies in the post-trial analysis, lack of efficacies in the primary end points raises similar concerns that we found in CUPID trials. Whether it was related to the failure of the trail design or the finding is just by chance remains to be carefully investigated.
Development of AAV Vectors With Improved Tropism for Cardiomyocytes
A mutually nonexclusive alternative to improving AAV delivery methods to increase cardiomyocyte transduction is the isolation of novel AAV variants with increased tropism for cardiomyocytes. These re-engineered vectors have been useful in expanding the uses of AAV vectors to a variety of tissues. Ideally, these variants could be administered systemically and would efficiently and preferentially transduce cardiomyocytes. That this might not be an unachievable fantasy is demonstrated by the efficient transduction of rodent cardiomyocytes by tail vein-injected AAV9 vectors. 93 Conceptually, the isolation of such variants can be divided into 2 classes: (1) the rational design of novel AAV variants, or (2) the use of large libraries of AAVs with diverse capsids combined with directed evolution.
Broadly, the rational design approaches are either based on the known 3-dimensional AAV capsid structures and the known receptor-binding regions of the major serotypes or they rely on targeting the AAV variant to a specific receptor by incorporating a peptide known to bind to a receptor of choice.
Asokan et al 94 used a rational design approach to isolate AAV variants with reduced hepatic tropism because the efficient uptake of AAV serotypes, such as AAV8 and AAV9, by the liver reduces the transduction efficiency of the desired target organs and carries the risk of deleterious effects on the liver. To this end, Samulski and colleagues took advantage of the fact that the critical residues of the binding site of AAV2 to its primary receptor, heparan sulfate proteoglycan have been identified previously. 95, 96 Asokan et al 94 then systematically replaced a hexapeptide containing the amino acids that are essential for the binding of AAV2 to heparan sulfate proteoglycan with the corresponding hexapeptides of AAV1, AAV3-5, and AAV7-9. One of those new variants (named AAV2i8), in which they replaced the AAV2 hexapeptide (RGNRQA) with the corresponding peptide from AAV8 (QQNTAP), showed broad muscle tropism, including the myocardium with comparatively low liver transduction when compared with AAV8. 94 To our knowledge, to date, there are no published attempts at targeting AAV to a putative cardiomyocyte-specific receptor by inserting a receptor-binding targeting peptide into the AAV capsid, and AAV2i8 (also called BNP116) remains the only rationally designed AAV variant that efficiently transduces cardiomyocytes.
A conceptually different approach relies on the creation of high complexity libraries of AAV variants with diverse capsids. There are numerous ways to create such libraries. These include the insertion of random peptides into a specific location of the AAV capsid (or the replacement of a capsid protein peptide sequence with a random peptide sequence), errorprone polymerase chain reaction, staggered extension polymerase chain reaction, or capsid shuffling to create chimeric AAV capsids composed of capsid proteins with sequences made up of stretches of amino acids from different serotypes ( Figure 3A) .
Ying et al 97 constructed an AAV capsid library by inserting a random heptamer into the heparan sulfate proteoglycan-binding site of AAV2. Using this library, they then performed several rounds of selection for cardiotropic AAVs using a similar method to the approach described in Figure 3B . But, whereas several vectors showed higher vector genome numbers in the heart when compared with AAV2 or a heparin-binding negative AAV2 mutant, none of the variants showed increased transgene expression when compared with AAV9. In fact, the most cardiotropic variant isolated resulted in a 100-fold lower expression level of luciferase compared with AAV9. 97 Yang et al 98 also used directed evolution to identify cardiotropic AAVs, but they used a shuffled capsid AAV library ( Figure 3A ) as opposed to a random peptide library. They isolated an AAV variant, M41, which in mice showed a 20-fold lower transduction of the liver when compared with AAV9, and the heart transduction was only 2-fold lower compared with AAV9. 98 Unfortunately, when delivered to pigs via antegrade intracoronary infusion, transduction of cardiomyocytes by M41 proved to be inefficient (Hajjar et al, unpublished results), pointing to species differences in AAV tropism. Maybe species-specific tropism should not be surprising because there are only a limited number of zoonotic viruses. Moreover, among parvoviruses, certain canine parvovirus strains can infect both dogs and cats whereas others are specific to dogs, and none of the canine parvovirus strains can infect humans.
Future Perspectives
Despite large disappointments in these clinical trials, we learned that the cardiac specific administration of vectors is safe and well tolerated in patients with advanced heart failure. For more robust transgene expression in patients, modifications to the vectors, dose, and delivery methods may be required. Increase in vector dose can boost cardiac vector uptake in a nonproportional manner. Indeed, we found that increasing the dose of the vector up to 10× (1×10 13 to 1×10 14 ) resulted in average 30-fold more increase in the cardiac vector uptake in pigs. 55 However, even though we are witnessing ever higher doses used in clinical trials for monogenic diseases, the recent reports of severe toxicity in nonhuman primates and pigs after the injection of high-dose intravenous administration of an AAV9 vector 99 demonstrate the significant risks of extensive vector dose escalations.
Vector modification approaches include changing the ratio of empty vectors, using stronger promoters, developing new vectors, and evading immune response. A new chimeric AAV vector, BNP116 (also called AAV2i8), 94 encoding constitutively active inhibitor 1 was approved for clinical use by FDA, and a phase1/2 clinical trial is currently prepared. Ways to modify delivery methods are also explored, and as mentioned above, stromal cell-derived factor-1 gene therapy has another program that uses retrograde coronary sinus delivery of the vectors. For patients undergoing open-chest surgeries, epicardial direct injection or atrial painting may be applied. Ex vivo gene transfer of vascular grafts and gene delivery using cardiopulmonary support may be applicable to patients undergoing certain procedures.
Not only the gene therapy vectors and delivery methods but also the clinical trial design needs to be improved. Target patient population, duration of follow-up, and efficacious end points are the key parameters that need careful consideration before starting the trial. Whether to include only the advanced cardiac disease patients or also the less advanced disease patients can likely affect the outcome. In this regard, noninvasive measures of identifying decreased expression of target genes may facilitate recruitment of optimal candidates for the trial. Blood assays that can detect reduced cardiac expression of target genes, for example, may help stratify patients suited for gene therapy. Research on small noncoding RNAs may open new diagnostics for these types of application. 100 For determining appropriate duration of the trial, noninvasive imaging of transgene product may help understand if the expression sustains long term or gradually fade and if the patients responds or not is related to the effect of gene therapy. Finding appropriate end points for clinical trial is always an issue, but it should rely on theoretical mechanistic background, evidence that are obtained in preclinical studies, and most importantly, should be associated with improved outcome of patient prognosis and symptoms. An apparent next milestone to achieve for cardiac gene therapy is to demonstrate therapeutic efficacy in large randomized clinical trials. However, the ultimate goal is to use gene therapy in routine clinical practice and improve patients' quality and quantity of lives. As we foresee several cardiac gene therapy clinical trials to be initiated in the next few years and envision some of them to proceed to phase 3 and thereafter the clinic, practical aspects of gene therapy application including manufacture, cost, reimbursement, and regulation need to be prepared. In fact, although Glybera received European Union market approval in 2012, only 1 patient has been reimbursed for its use throughout the Europe. 101 The price of the treatment was ≈€900 000, and the drug was withdrawn from the market in 2017 because of its high cost and limited demand. Meanwhile, the amount of vector needed to transduce sufficiently a heart seems larger than we initially expected, and large-scale production of vectors is indispensable. Active discussions from manufacture to insurance are ongoing to solve these problems. Newer gene therapy programs that are likely to be approved by FDA in near future, such as those for hemophilia, may guide cardiac gene therapy's clinical integration after successful next step.
Conclusions
Gene therapy for the treatment of monogenic diseases will continue to make great strides in clinical applications. Success in clinical cardiac gene therapy will probably come first from monogenic diseases that can be targeted by gain-of-function or loss-of-function strategies. Effective treatments of more complex cardiac diseases will follow soon after.
